GlassScriptPhysician profile
Mallory D Morrow
NPI 1205316288
$2,159.78
in general payments reported to CMS, 2019-2025
28 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $353 · 2023: $537 · 2024: $521 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $325.29 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $214.20 | 2021-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $209.95 | 2021-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.72 | 2021-2024 | Xifaxan, Trulance |
| Radius Health, INC. | $128.35 | 2021-2025 | Tymlos |
| Novo Nordisk INC | $116.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $105.00 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $104.03 | 2021-2025 | Rexulti |
| Abbvie INC. | $103.78 | 2021-2025 | |
| Daiichi Sankyo INC. | $100.47 | 2022-2023 | Injectafer |
| Scilex Pharmaceuticals INC. | $73.47 | 2022-2023 | Ztlido |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.15 | 2021-2023 | Synjardy |
| Abbott Laboratories | $63.84 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $53.99 | 2021-2025 | |
| Mylan Specialty L.P. | $44.46 | 2022-2023 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.23 | 2023-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $32.96 | 2022-2023 | |
| Antares Pharma, INC. | $31.47 | 2024 | Xyosted |
| Amarin Pharma, INC. | $26.98 | 2021 | |
| Eisai INC. | $23.95 | 2024 | |
| Dexcom, INC. | $20.57 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.03 | 2021 | |
| Halozyme INC | $17.26 | 2023 | |
| Mannkind Corporation | $15.57 | 2025 | |
| Aimmune Therapeutics, INC. | $15.10 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.42 | 2022 | |
| Amgen INC. | $13.02 | 2023 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.